Biotechnology Results of the VARSITY trial, a head-to-head Phase IIIb double-blind, double-dummy, multicenter active controlled study, that evaluates the efficacy and safety of Japan pharma major Takeda’s Entyvio (vedolizumab), compared to AbbVie’s Humira (adalimumab) in patients with moderate to severe ulcerative colitis (UC), were announced at the ECCO Conference 2019 in Copenhagen, and look set to have an impact on the therapy sector. 13 March 2019